1-tert-butyl-4-methyl-1,6-dihydro-7H-pyrazolo[3,4-d]pyridazin-7-one, 95.0%, 250mg

1-Bromo-4-(2-bromoethoxy)benzene, 95.0%, 5g

Plan PLPH S40x/0.65 phase contrast objective

3,5-Bis(trifluoromethyl)acetanilide, 97.0%, 25g

5-Mercapto-2-methoxy-4-methylbenzoic acid, 95%, 1g

7-bromo-2,4,6-trichloro-8-fluoroquinazoline, 95.0%, 1g

(S)-methyl 2-((R)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoate, 97%, 250mg

1-Pyridin-2-ylmethylpiperidin-4-one, 95.0%, 2.5g

2-Aminophenol, 98.0%, 100g

tert-Butyl 4-((2-bromo-4-fluorophenyl)amino)-4-cyanopiperidine-1-carboxylate, 98%, 2g

(S)-2-((tert-Butoxycarbonyl)amino)-3-cyanopropanoic acid, 95.0%, 1g

4-CHLORO-2-(METHOXYCARBONYL)PHENYLBORONIC ACID, 95.0%, 5g

1-(6-Bromopyridin-3-yl)ethan-1-ol, 97%, 5g